PSA Doubling Time (PSADT) Calculator
ورودیهای بالینی بیمار
حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL
حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days
حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL
حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days
حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL
حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days
حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL
حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days
حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL
حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Very High Risk0–3
- High Risk3–6
- Intermediate Risk6–12
- Low Risk12–36
The PSA Doubling Time (PSADT) Calculator calculates calculating PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. Key inputs include psa 1. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.
Clinical Indication
The PSA Doubling Time (PSADT) Calculator is indicated for bedside clinical practice to support Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care. Clinical exclusion: Not applicable for initial prostate cancer screening or untreated patients.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Used only for patients with biochemical recurrence after treatment.
PSADT = ln(2) / slope, where slope is derived from linear regression of ln(PSA) vs time
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| psa_1 | float | Yes | First PSA measurement in ng/mL(ng/mL) |
| days_1 | integer | Yes | Days from baseline for first PSA measurement(days) |
| psa_2 | float | Yes | Second PSA measurement in ng/mL(ng/mL) |
| days_2 | integer | Yes | Days from baseline for second PSA measurement(days) |
| psa_3 | float | No | Third PSA measurement in ng/mL (optional)(ng/mL) |
| days_3 | integer | No | Days from baseline for third PSA measurement (optional)(days) |
| psa_4 | float | No | Fourth PSA measurement in ng/mL (optional)(ng/mL) |
| days_4 | integer | No | Days from baseline for fourth PSA measurement (optional)(days) |
| psa_5 | float | No | Fifth PSA measurement in ng/mL (optional)(ng/mL) |
| days_5 | integer | No | Days from baseline for fifth PSA measurement (optional)(days) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–3 | Very High Risk | Rapid PSA progression |
| 3–6 | High Risk | Fast PSA progression |
| 6–12 | Intermediate Risk | Moderate PSA progression |
| 12–36 | Low Risk | Slow PSA progression |
| 36–1000 | Very Low Risk | Very slow PSA progression |
Evidence-Based References (EBM)
- D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95(18):1376-83. doi: 10.1093/jnci/djg043.DOI: 10.1093/jnci/djg043
- Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433-9. doi: 10.1001/jama.294.4.433.DOI: 10.1001/jama.294.4.433
- Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-7. doi: 10.1001/jama.281.17.1591.DOI: 10.1001/jama.281.17.1591
- Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23(28):6992-8. doi: 10.1200/JCO.2005.01.2906.DOI: 10.1200/JCO.2005.01.2906